

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



天津泰達生物醫學工程股份有限公司  
**Tianjin TEDA Biomedical Engineering Company Limited**  
*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
(Stock code: 8189)

## **REDESIGNATION OF DIRECTOR AND PROPOSED AMENDMENTS TO THE ARTICLES**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”, together with its subsidiaries and consolidated associates, collectively referred to as the “**Group**”) hereby announces that, Mr. Xia Alan Zhe (“**Mr. Xia**”), an executive Director of the Company, has applied to be redesignated from the position of executive Director to non-executive Director of the Company due to regulatory restrictions associated with his holding of the Hong Kong Securities and Futures Commission Type 9 (Asset Management) responsible officer (RO) license. Since his appointment, Mr. Xia has not been involved in the day-to-day management of the Company.

Article 91 of the Company’s current Articles states: The board of directors comprises 9 directors, of which 3 are executive directors, 3 are independent non-executive directors and 3 are non-executive directors. The Board shall have a chairman and a vice-chairman.

The Company currently has a total of 3 non-executive directors, namely Mr. He Xin, Dr. Li Ximing and Mr. Wang Lei. If Mr. Xia was directly redesignated from an executive Director to a non-executive Director, this would violate the limit on the number of non-executive Directors set forth in the Company’s Articles. Accordingly, the Board of the Company resolves to adjust the structure of the Board and to amend article 91 of the Articles as follows: The board of directors comprises 9 directors, of which 2 are executive directors, 3 are independent non-executive directors and 4 are non-executive directors. The Board shall have a chairman.

The aforementioned amendments to the Articles of Association are subject to the approval by the shareholders through a special resolution at the annual general meeting and the filing requirements with the Administration for Industry and Commerce have been fulfilled. A notice of the annual general meeting containing details of the relevant resolution will be sent to the shareholders as soon as practicable, together with a circular setting out the proposed amendments to the Articles.

Mr. Xia's redesignation from an executive Director to a non-executive Director are subject to the approval of the resolution of the amendments to the Articles of Association at the annual general meeting and completion of the filing with the administrative department for industry and commerce. Until the above redesignation officially takes effect, Mr. Xia will not participate in the Company's day-to-day management affairs.

Mr. Xia will enter into a new service agreement with the Company (the "**New Service Agreement**") after the redesignation takes effect, and his appointment shall be subject to the provisions regarding rotation and re-election at general meetings in accordance with the Company's Articles of Association and the Listing Rules.

Mr. Xia Alan Zhe ("**Mr. Xia**"), aged 52, holds a bachelor's degree in economics from School of Business Sun Yat-sen University and a master of business administration degree from Australia Graduate School of Management (AGSM). He is a type-9 licensed responsible officer of Hong Kong, and holds the qualification of certified practising accountant of Australia. He has been deeply engaged in cross-border investment, alternative asset operations and fund management for over twenty years and possesses extensive experience in investment and financing and platform establishment. From 2000 to 2008: held positions including finance manager of two Australian telecommunications giants, namely Optus and Telstra, responsible for M&A analysis, capital project accounting and large-scale expense budget planning, laying his foundation in financial and capital operations. From 2008 to 2015: successively served as director and executive director at UBS Global Asset Management (China) Co., Ltd., leading cross-border fund raising, real estate investment and debt financing. From 2016 to 2023: served as senior managing director and founding partner at SDIC RE Asset Management Co., Ltd. (國投萬和資產管理有限公司), building investment platforms and leading investment strategy formulation, completing large-scale cross-border investment and financing layout. From 2023 to date: served as managing director and licensed responsible officer (RO) at INV Advisory Limited (place of registration in Hong Kong), leading non-performing assets, REITs business and Southeast Asia cross-border investment. Mr. Xia was appointed as an executive Director of the Company on December 31, 2025.

Following Mr. Xia's redesignation from an executive Director to a non-executive Director, his remuneration remains unchanged at RMB80,000 per annum. The Company will reimburse Mr. Xia for expenses incurred in the performance of his duties as a non-executive Director. Mr. Xia's annual remuneration as a non-executive Director is determined by the Board based on the recommendations of the remuneration Committee of the Company (the "**Remuneration Committee**"), taking into account market remuneration levels as well as Mr. Xia's qualifications and experience. Mr. Xia's remuneration will be reviewed from time to time by the Remuneration Committee and the Board in accordance with the Articles of the Company and the powers granted by the shareholders of the Company at the Company's general meeting.

As at the date of this announcement, Mr. Xia did not (i) have any relationship with any Director, senior management, substantial or controlling shareholder (as defined in the Listing Rules) of the Company; (ii) hold any position in the Company or any other members of the Group; (iii) have any interest in the shares of the Company as defined in Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); or (iv) hold any other significant appointments or professional qualifications; (v) hold any directorship in any public company whose securities are listed on any securities market in Hong Kong or overseas within the three years prior to the date of this announcement. Save as disclosed in this announcement, the Board is not aware of any other information regarding the aforementioned redesignation that is required to be disclosed pursuant to any provision of GEM Listing Rules 17.50(2), nor are there any other matters that require the attention of the Company's shareholders.

By order of the Board

**Tianjin TEDA Biomedical Engineering Company Limited**

**Sun Li**

*Chairman*

Tianjin, the PRC

30 April 2026

*As at the date of this announcement, the executive directors of the Company are Ms. Sun Li, Mr. Yang Zeng and Mr. Xia Alan Zhe; the non-executive directors of the Company are Mr. He Xin, Dr. Li Ximing and Mr. Wang Lei; the independent non-executive directors of the Company are Ms. Gao Chun, Mr. Tu Xiangzhen and Mr. Chen Jiang.*

*This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Listed Company Information” page for seven days from the date of its posting, and it will also be published and remain on the website of the Company at [www.bioteda.com](http://www.bioteda.com).*